News

Recent updates from Akiram Therapeutics.

Subscribe here to receive new and press releases to you email.


Akiram Therapeutics announces agreement with leading university hospital on 177Lu-AKIR001 manufacturing for cancer therapy
Press Release

Akiram Therapeutics announces agreement with leading university hospital on 177Lu-AKIR001 manufacturing for cancer therapy

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, has entered into an agreement with a leading Swedish university hospital for the manufacturing of 177Lu-AKIR001, a radiopharmaceutical designed for treating patients with solid tumors. This agreement marks an important step towards the Phase I first-in-human study, which is planned to start in 2024. Akiram…

Akiram Therapeutics strengthens board with drug development expertise
Press Release

Akiram Therapeutics strengthens board with drug development expertise

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, is pleased to announce the addition of Anna Törner and Peder Walberg to its board of directors. Their combined expertise in drug development and regulatory affairs fortifies the company’s position as it advances toward the planned clinical trials of an innovative cancer treatment in 2024….

Akiram Therapeutics’ pioneering cancer research backed by SEK 6 million from the Erling-Persson Foundation
Press Release

Akiram Therapeutics’ pioneering cancer research backed by SEK 6 million from the Erling-Persson Foundation

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, is pleased to announce that the company’s founder, Professor Marika Nestor and her research group at Uppsala University have been granted SEK 6 million by the Erling-Persson Foundation. This funding will advance a groundbreaking research project aimed at developing novel radiopharmaceuticals for the treatment of…

Akiram Therapeutics to present promising data on the therapeutic potential of its drug candidate at EANM Congress
Press Release

Akiram Therapeutics to present promising data on the therapeutic potential of its drug candidate at EANM Congress

Akiram Therapeutics, a Swedish biotech company specializing in radiotherapy will present promising preclinical data at the European Association of Nuclear Medicine (EANM) Congress taking place in Vienna, Austria on September 9–13. The data showcases the potential of the company’s radiopharmaceutical 177Lu-AKIR001 targeting tumor lesions for therapeutic purposes. A Phase 1 study is planned for 2024….

Akiram Therapeutics raises SEK 68 million for clinical development of a drug candidate for rare thyroid cancers
Press Release

Akiram Therapeutics raises SEK 68 million for clinical development of a drug candidate for rare thyroid cancers

The Swedish radioimmunotherapy company Akiram Therapeutics, developing targeted cancer therapy, has raised SEK 68 million in a share issue led by Sciety and the network Sciety Venture Partners. The investment company Linc AB participated in the share issue with SEK 20 million. The proceeds from the financing will be used for GMP production of the…

She is creating brilliant chances for cancer patients
News

She is creating brilliant chances for cancer patients

Radiopharmaceuticals that fight cancer are on the rise and Marika Nestor is doing everything she can to contribute to their development. An antibody from her lab offers hope for a future treatment for those affected by anaplastic thyroid cancer, a currently incurable form of cancer. Read the full news item from Uppsala University here (in…

Latest DDD-exit: Radioactive antibody for treatment of aggressive cancer
News

Latest DDD-exit: Radioactive antibody for treatment of aggressive cancer

A new antibody might be the first effective treatment for Anaplastic thyroid cancer (ATC), a very aggressive cancer type with a median survival of only 4-5 month even with available treatments. The radiolabeled antibody is the result of a four-year long successful collaboration between SciLifeLab researcher Marika Nestor (Uppsala University) and the SciLifeLab Drug Discovery…